Literature DB >> 32415816

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.

Semir Bešlija1, Zdenka Gojković2, Timur Cerić1, Alma Mekić Abazović3, Inga Marijanović4, Semir Vranić5, Jasminka Mustedanagić-Mujanović6, Faruk Skenderi1, Ivanka Rakita2, Aleksandar Guzijan2, Dijana Koprić6, Alen Humačkić7, Danijela Trokić8, Jasmina Alidžanović6, Alma Efendić3, Ibrahim Šišić3, Harun Drljević3, Vanesa Bešlagić1, Božana Babić2, Azra Pašić3, Anela Ramić3, Dijana Mikić2, Zlatko Guzin7, Dragana Karan4, Teo Buhovac4, Dragana Miletić4, Senad Šečić1, Azra Đozić Šahmić1, Lejla Mujbegović3, Alisa Kubura3, Mensura Burina6, Nenad Lalović9, Nikolina Dukić9, Jelena Vladičić Mašić9, Mirjana Ćuk9, Rajna Stanušić9.   

Abstract

The HERe2Cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist.

Entities:  

Year:  2021        PMID: 32415816      PMCID: PMC7982071          DOI: 10.17305/bjbms.2020.4846

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  19 in total

Review 1.  St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion.

Authors:  Michael Gnant; Christoph Thomssen; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2015-04       Impact factor: 2.860

2.  Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Authors:  Ramon Colomer; Cristina Saura; Pedro Sánchez-Rovira; Tomás Pascual; Isabel T Rubio; Octavio Burgués; Lourdes Marcos; César A Rodríguez; Miguel Martín; Ana Lluch
Journal:  Oncologist       Date:  2019-02-01

3.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

4.  Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Authors:  Michael Untch; Peter A Fasching; Gottfried E Konecny; Stephan Hasmüller; Annette Lebeau; Rolf Kreienberg; Oumar Camara; Volkmar Müller; Andreas du Bois; Thorsten Kühn; Elmar Stickeler; Nadia Harbeck; Cornelia Höss; Steffen Kahlert; Thomas Beck; Werner Fett; Keyur M Mehta; Gunter von Minckwitz; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

Review 5.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

6.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Authors:  A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

7.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Sandra M Swain; Sung-Bae Kim; Javier Cortés; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Adam Knott; Emma Clark; Graham Ross; Mark C Benyunes; José Baselga
Journal:  Lancet Oncol       Date:  2013-04-18       Impact factor: 41.316

Review 8.  St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment.

Authors:  Marija Balic; Christoph Thomssen; Rachel Würstlein; Michael Gnant; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2019-04-04       Impact factor: 2.860

9.  Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.

Authors:  F Boccardo; A Rubagotti; A Perrotta; D Amoroso; M Balestrero; A De Matteis; P Zola; P Sismondi; G Francini; R Petrioli
Journal:  Ann Oncol       Date:  1994-04       Impact factor: 32.976

10.  Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer
Journal:  N Engl J Med       Date:  2018-12-05       Impact factor: 176.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.